SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Bärlund Maarit)
 

Sökning: WFRF:(Bärlund Maarit) > Detailed analysis o...

  • Kinos, SampsaTampere Univ Hosp, Tays Canc Ctr, Dept Oncol, Tampere, Finland.;Univ Tampere, Fac Med & Hlth Technol, Tampere, Finland. (författare)

Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • Medical Journals Sweden,2024
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-532554
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-532554URI
  • https://doi.org/10.2340/1651-226X.2024.24023DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:238698698URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:158371966URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background and purpose: The CardioSwitch-study demonstrated that patients with solid tumors who develop cardiotoxicity on capecitabine or 5-fluorouracil (5-FU) treatment can be safely switched to S-1, an alternative fluoropyrimidine (FP). In light of the European Medicines Agency approval of S-1 in metastatic colorectal cancer (mCRC), this analysis provides more detailed safety and efficacy information, and data regarding metastasectomy and/or local ablative therapy (LAT), on the mCRC patients from the original study.Materials and methods: This retrospective cohort study was conducted at 12 European centers. The primary endpoint was recurrence of cardiotoxicity after switch. For this analysis, safety data are reported for 78 mCRC patients from the CardioSwitch cohort (N = 200). Detailed efficacy and outcomes data were available for 66 mCRC patients.Results: Data for the safety of S-1 in mCRC patients were similar to the original CardioSwitch cohort and that expected for FP-based treatment, with no new concerns. Recurrent cardiotoxicity (all grade 1) with S-1-based treatment occurred in 4/78 (5%) mCRC patients; all were able to complete FP treatment. Median progression-free survival from initiation of S-1-based treatment was 9.0 months and median overall survival 26.7 months. Metastasectomy and/or LAT was performed in 33/66 (50%) patients, and S-1 was successfully used in recommended neoadjuvant/conversion or adjuvant-like combination regimens and schedules as for standard FPs.Interpretation: S-1 is a safe and effective FP alternative when mCRC patients are forced to discontinue 5-FU or capecitabine due to cardiotoxicity and can be safely used in the standard recommended regimens, settings, and schedules.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Hagman, HelgaSkane Univ Hosp, Dept Oncol, Malmö, Sweden. (författare)
  • Halonen, PäiviHelsinki Univ Hosp, Univ Helsinki, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland. (författare)
  • Soveri, Leena-MaijaHelsinki Univ Hosp, Univ Helsinki, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland. (författare)
  • O'Reilly, MarySt Vincents Univ Hosp, Dept Oncol, Dublin, Ireland.;Univ Coll Dublin, Dublin, Ireland. (författare)
  • Pfeiffer, PerKarolinska Institutet,Odense Univ Hosp, Dept Oncol, Odense, Denmark. (författare)
  • Frödin, Jan-ErikKarolinska Institutet,Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden. (författare)
  • Sorbye, HalfdanUniv Bergen, Haukeland Univ Hosp, NO-5021 Bergen, Norway. (författare)
  • Heervä, EetuTurku Univ Hosp, Dept Oncol, Turku, Finland.;Univ Turku, Turku, Finland. (författare)
  • Liposits, GaborReg Hosp West Jutland, Dept Oncol, Herning, Denmark. (författare)
  • Kallio, RaijaOulu Univ, Dept Oncol, Oulu, Finland.;Univ Hosp Oulu, Oulu, Finland. (författare)
  • Ålgars, AnnikaTurku Univ Hosp, Dept Oncol, Turku, Finland.;Univ Turku, Turku, Finland. (författare)
  • Ristamäki, RaijaTurku Univ Hosp, Dept Oncol, Turku, Finland.;Univ Turku, Turku, Finland. (författare)
  • Salminen, TapioTampere Univ Hosp, Tays Canc Ctr, Dept Oncol, Tampere, Finland.;Univ Tampere, Fac Med & Hlth Technol, Tampere, Finland. (författare)
  • Bärlund, MaaritTampere Univ Hosp, Tays Canc Ctr, Dept Oncol, Tampere, Finland.;Univ Tampere, Fac Med & Hlth Technol, Tampere, Finland. (författare)
  • Shah, Carl-HenrikKarolinska Univ Hosp, Dept Oncol, Stockholm, Sweden. (författare)
  • Mcdermott, RaySt Vincents Univ Hosp, Dept Oncol, Dublin, Ireland.;Univ Coll Dublin, Dublin, Ireland. (författare)
  • Röckert, RebeckaDepartment of Oncology, Uppsala University Hospital, Uppsala, Sweden (författare)
  • Flygare, PetraSundsvall Hosp, Dept Oncol, Sundsvall, Sweden. (författare)
  • Kwakman, JohannesUniv Med Ctr Utrecht, Utrecht Univ, Dept Med Oncol, Utrecht, Netherlands. (författare)
  • Teske, ArcoUniv Med Ctr, Utrecht Univ, Dept Cardiol, Utrecht, Netherlands. (författare)
  • Punt, CornelisUniv Utrecht, Univ Med Ctr Utrecht, Jules Ctr Hlth Sci & Primary Care, Dept Epidemiol, Utrecht, Netherlands. (författare)
  • Glimelius, BengtDepartment of Oncology, Uppsala University Hospital, Uppsala, Sweden(Swepub:uu)bengglim (författare)
  • Österlund, PiaTampere Univ Hosp, Tays Canc Ctr, Dept Oncol, Tampere, Finland.;Univ Tampere, Fac Med & Hlth Technol, Tampere, Finland.;Helsinki Univ Hosp, Univ Helsinki, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.;Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden.;Karolinska Univ Hosp, Dept GI Canc, Tema Canc, Stockholm, Sweden. (författare)
  • Tampere Univ Hosp, Tays Canc Ctr, Dept Oncol, Tampere, Finland.;Univ Tampere, Fac Med & Hlth Technol, Tampere, Finland.Skane Univ Hosp, Dept Oncol, Malmö, Sweden. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Acta Oncologica: Medical Journals Sweden63, s. 248-2580284-186X1651-226X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy